These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2984982)

  • 21. Rat interferons. VI. Heterologous interferon in the treatment of viral infections.
    Lobodzińska M; Albin M
    Arch Immunol Ther Exp (Warsz); 1979; 27(1-2):247-52. PubMed ID: 220932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon administered orally: protection of neonatal mice from lethal virus challenge.
    Schafer TW; Lieberman M; Cohen M; Came PE
    Science; 1972 Jun; 176(4041):1326-7. PubMed ID: 4338344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of exogenous interferon treatment initiated after onset of multiplication of vesicular stomatitis virus in the brains of mice.
    Gresser I; Tovey MG; Bourali-Maury C
    J Gen Virol; 1975 Jun; 27(3):395-8. PubMed ID: 167120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell and virus sensitivity studies with recombinant human alpha interferons.
    Kramer MJ; Dennin R; Kramer C; Jones G; Connell E; Rolon N; Gruarin A; Kale R; Trown PW
    J Interferon Res; 1983; 3(4):425-35. PubMed ID: 6323591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elicitation of natural killer cells in beige mice by infection with vesicular stomatitis virus.
    McKinnon KP; Hale AH; Ruebush MJ
    Infect Immun; 1981 Apr; 32(1):204-10. PubMed ID: 6163720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Properties of human alpha-interferon F and hybrid interferon F/D obtained from recombinant bacteria compared to the properties of an interferon preparation from human leukocytes].
    Ovchinnikov IuA; Sverdlov ED; Tsarev SA; Monastyrskaia GS; Khodkova EM
    Dokl Akad Nauk SSSR; 1983; 268(4):996-1000. PubMed ID: 6187523
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes.
    Brooks TJ; Phillpotts RJ
    Antiviral Res; 1999 Feb; 41(1):57-64. PubMed ID: 10321579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bovine interferon-alphaI 1 is an effective inhibitor of bovine herpes virus-1 induced respiratory disease.
    Czarniecki CW; Anderson KP; Fennie EB; Bielefeldt Ohmann H; Babiuk LA
    Antiviral Res; 1985; Suppl 1():209-15. PubMed ID: 3002257
    [No Abstract]   [Full Text] [Related]  

  • 29. Mx gene control of interferon action: different kinetics of the antiviral state against influenza virus and vesicular stomatitis virus.
    Arnheiter H; Haller O
    J Virol; 1983 Sep; 47(3):626-30. PubMed ID: 6312087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant interferons alpha and gamma: comparative antiviral activity and synergistic interaction in encephalomyocarditis virus infection of mice.
    Sim IS; Cerruti RL
    Antiviral Res; 1987 Nov; 8(4):209-21. PubMed ID: 3128162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse interferon receptors: a difference in their response to alpha and beta interferons.
    Gordon I; Stevenson D; Tumas V; Natham CR
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2777-80. PubMed ID: 6319561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the mechanism of the interferon-mediated antiviral state to vesicular stomatitis virus in resting mouse peritoneal macrophages.
    Di Francesco P; Coccia EM; Gessani S; Romeo G; Borghi P; Locardi C; Belardelli F
    J Gen Virol; 1989 Jul; 70 ( Pt 7)():1899-905. PubMed ID: 2544669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HIV-1 activity of recombinant and hybrid species of interferon-alpha.
    Sperber SJ; Gocke DJ; Haberzettl C; Kuk R; Schwartz B; Pestka S
    J Interferon Res; 1992 Oct; 12(5):363-8. PubMed ID: 1331260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus.
    De Clercq E; De Somer P
    Life Sci; 1968 Sep; 7(17):925-33. PubMed ID: 4309814
    [No Abstract]   [Full Text] [Related]  

  • 35. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers.
    Witter F; Barouki F; Griffin D; Nadler P; Woods A; Wood D; Lietman P
    Clin Pharmacol Ther; 1987 Nov; 42(5):567-75. PubMed ID: 2445516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Replication of vesicular stomatitis virus in mouse spleen cells.
    Hecht TT; Paul WE
    Infect Immun; 1981 Jun; 32(3):1014-23. PubMed ID: 6265370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral and antitumor effects of a human interferon analog, IFN-alpha Con 1, assessed in hamsters.
    Altrock BW; Fagin KD; Hockman HR; Fish EN; Goldstein L; Chang D; Duker K; Stebbing N
    J Interferon Res; 1986 Aug; 6(4):405-15. PubMed ID: 3021874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral activity in interferon-treated bovine tracheal organ cultures.
    Fulton RW; Root SK
    Infect Immun; 1978 Aug; 21(2):672-3. PubMed ID: 211089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic intranasal alpha 2 interferon and viral exacerbations of chronic respiratory disease.
    Wiselka MJ; Nicholson KG; Kent J; Cookson JB; Tyrrell DA
    Thorax; 1991 Oct; 46(10):706-11. PubMed ID: 1750016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of recombinant murine interferon-gamma and human interferon-alpha A/D(Bgl) administered in concert and their influence on natural killer cell function in mice.
    Chen SA; Shalaby MR; Crase DR; Palladino MA; Baughman RA
    J Interferon Res; 1988 Oct; 8(5):597-608. PubMed ID: 3148670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.